BlossomHill Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jing Rong Jean Cui
- Full Time Employees
- 63
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10255 Science Center Drive, Suite 200 San Diego CA United States of America 92121
- IPO Date
- Aug 7, 2026
- CIK
- 0001839970
- Website
- bhtherapeutics.com
- Similar Companies
- Business
- BlossomHill Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics for oncology and autoimmune diseases. The company focuses on innovative biologics and small-mue modalities targeting validated and novel pathways with potential disease-modifying effects. Primary business activity centers on research and development, clinical trial execution, regulatory submission support, and collaboration-driven manufacturing and service offerings. Headquartered in Wilmington, Delaware, BlossomHill operates research and development facilities in the United States and Europe, with additional manufacturing and pilot-scale operations in North America and Asia. Founding year is 2020. Main products and services: biologics and small-mue therapeutic candidates across preclinical and clinical stages; drug discovery and target validation services; translational science, biomarker development, and companion diagnostic support; formulation development, GMP manufacturing scalability; regulatory affairs consulting and strategic advisory services; clinical trial design, protocol development, and management; partnering and licensing opportunities; geographic commercialization via regional partnerships; ongoing preclinical studies, clinical development programs, and outsourced research services. Latest major company changes: enters strategic partnerships with pharmaceutical and academic collaborators to advance multiple candidates; completes Series B funding round to accelerate pipeline progression; acquires adjacent biotech assets to expand platform capabilities; launches new phase I/II clinical programs; reorients portfolio toward oncology and autoimmune indications; consolidates operations under a unified corporate structure; expands manufacturing footprint to support anticipated clinical-stage supply; appoints key executives to reinforce R&D and commercial enablement. These developments reflect recent alliances, financings, pipeline expansions, and organizational restructuring within the last 1–2 years. Additional context: industry focuses on biotechnology and pharmaceutical development; targets biopharma and research partners, contract development and manufacturing organizations (CDMOs), and academic collaborators; geographic presence spans North America, Europe, and Asia with subsidiaries and regional offices supporting global development and potential commercialization planning. Parent company relationships and subsidiary structures include strategic governance aligned to a centralized R&D and regulatory strategy.
Company News
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Down 4.9% – Time to Sell?
BlossomHill Therapeutics (NASDAQ:BLSM) Shares Gap Up – Here’s Why
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
BlossomHill Therapeutics, Inc.’s Quiet Period Set To Expire on September 16th (NASDAQ:BLSM)
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
BlossomHill Therapeutics (NASDAQ:BLSM) Director Bihua Chen Purchases 312,500 Shares of Stock
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
BlossomHill Therapeutics Aims For $125 Million IPO On Cancer Treatment Pipeline Promise